1. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis 
Peter H. Howarth, MBBS, FRCPa, Martin A. Stern, BMBCh, FRCPb, Larry Roi, PhDc, Robert Reynolds, PhDd, Jean Bousquet, MDe 
Journal of Allergy and Clinical Immunology 
Volume 104, Issue 5, Pages (November 1999)
DOI: /S (99)
Copyright © 1999 Mosby, Inc. Terms and Conditions

2. Fig. 1
Mean (±SE) change in 24-hour reflective TSS with use of ITT population. Three asterisks, P ≤ versus placebo. Mean ± SE baseline scores were 7.3 ± 0.1 for patients who received either placebo or cetirizine (10 mg), 7.2 ± 0.1 for those who received fexofenadine (120 mg), and 7.4 ± 0.1 for fexofenadine (180 mg) group. There were no significant differences among active treatment groups.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions

3. Fig. 2
Mean (±SE) change in morning instantaneous TSS (at trough drug levels before daily medication) with use of ITT population. Asterisks indicate level of significance versus placebo: one asterisk, P < .003, and three asterisks, P ≤ versus placebo. Mean ± SE baseline scores were 7.1 ± 0.2 for patients who received either placebo or cetirizine (10 mg), 7.0 ± 0.2 for those who received fexofenadine (120 mg), and 6.9 ± 0.2 for fexofenadine (180 mg) group. There were no significant differences among active treatment groups.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions

4. Fig. 3
Incidence of most frequent treatment-related adverse events with placebo, fexofenadine HCl (120 and 180 mg), and cetirizine administered QD.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions